Current Cardiology Reports

, 16:510

Arrhythmias in Structural Heart Disease

  • H. Sawyer Gillespie
  • Charles C. H. Lin
  • Jordan M. Prutkin
Invasive Electrophysiology and Pacing (EK Heist, Section Editor)
  • 259 Downloads
Part of the following topical collections:
  1. Topical Collection on Invasive Electrophysiology and Pacing

Abstract

The presence of structural heart disease is often associated with the development of electrical abnormalities of the heart, manifesting as atrial and ventricular arrhythmias. These can occur in those with ischemic and nonischemic cardiomyopathies, congenital heart disease, and various acquired and intrinsic structural abnormalities of the myocardium. Treatment of these arrhythmias generally involves treatment of the underlying disorder first, if possible, such as with surgical or catheter-based intervention. Other therapies, including medical therapy with beta-blockers and anti-arrhythmic agents, pacemakers and implantable cardioverter-defibrillators (ICDs), and ablation may be offered both as prophylactic therapy or if arrhythmias have developed. In some instances, therapy is undertaken regardless of whether there are symptoms. ICDs provide support for those patients at risk for malignant, life-threatening arrhythmias, but appropriate patient and device selection are vital to improve mortality and to limit adverse events.

Keywords

Atrial fibrillation Ventricular fibrillation Ventricular tachycardia Cardiomyopathy Congenital heart disease Arrhythmias Structural heart disease 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. J Am Med Assoc. 1994;271:840–4.CrossRefGoogle Scholar
  2. 2.
    Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91:2D–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol. 2014. doi:10.1016/j.ijcard.2013.12.180.Google Scholar
  5. 5.••
    Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269–367. This guideline is the most thorough review of management of atrial fibrillation in those with and without cardiomyopathy.PubMedCrossRefGoogle Scholar
  6. 6.
    Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control vs rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.PubMedCrossRefGoogle Scholar
  8. 8.
    Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone vs sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide Study Group. N Engl J Med. 1999;341:857–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.PubMedCrossRefGoogle Scholar
  13. 13.
    Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359:1778–85.PubMedCrossRefGoogle Scholar
  16. 16.•
    Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A randomized trial to assess catheter ablation vs rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61:1894–903. This randomized controlled trial in patients with persistent atrial fibrillation demonstrated that atrial fibrillation ablation improved peak VO2 compared with rate control. Single procedure ablation success rate was 72%. Ejection fraction improved more in the ablation group, but the increase was nonsignificant.PubMedCrossRefGoogle Scholar
  17. 17.•
    Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol. 2012;59:719–26. This systematic review analyzed 6 studies with 768 patients undergoing cardiac resynchronization therapy. AV nodal ablation was associated with an increase in biventricular pacing, decrease in mortality, and improvement in New York Heart Association Class.PubMedCrossRefGoogle Scholar
  18. 18.
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart Disease and Stroke Statistics—2014 Update: a report from the American Heart Association. Circulation. 2014;129:e28–292.PubMedCrossRefGoogle Scholar
  19. 19.
    Havmoeller R, Reinier K, Teodorescu C, Uy-Evanado A, Mariani R, Gunson K, et al. Low rate of secondary prevention ICDs in the general population: multiple-year multiple-source surveillance of sudden cardiac death in the Oregon Sudden Unexpected Death Study. J Cardiovasc Electrophysiol. 2013;24:60–5.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Lopera G, Stevenson WG, Soejima K, Maisel WH, Koplan B, Sapp JL, et al. Identification and ablation of three types of ventricular tachycardia involving the his-purkinje system in patients with heart disease. J Cardiovasc Electrophysiol. 2004;15:52–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Effect of the anti-arrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327:227–33.CrossRefGoogle Scholar
  22. 22.
    Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRefGoogle Scholar
  23. 23.
    Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. J Am Med Assoc. 2006;295:165–71.CrossRefGoogle Scholar
  24. 24.
    Gao D, Van Herendael H, Alshengeiti L, Dorian P, Mangat I, Korley V, et al. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. J Cardiovasc Pharmacol. 2013;62:199–204.PubMedCrossRefGoogle Scholar
  25. 25.•
    Bunch TJ, Mahapatra S, Murdock D, Molden J, Weiss JP, May HT, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600–6. While small, this case series demonstrated that the sodium channel blocker effect of ranolazine seen in vitro has clinical implications for reduction ICD shocks in patients with ventricular tachycardia, offering a new anti-arrhythmic option.PubMedCrossRefGoogle Scholar
  26. 26.••
    Stevenson WG. Current treatment of ventricular arrhythmias: state of the art. Heart Rhythm. 2013;10:1919–26. This review article from one of the leaders in the field of ventricular tachycardia ablation is a thorough review of the management of ventricular arrhythmias.PubMedCrossRefGoogle Scholar
  27. 27.
    Zeppenfeld K, Stevenson WG. Ablation of ventricular tachycardia in patients with structural heart disease. Pacing Clin Electrophysiol. 2008;31:358–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Sasaki T, Miller CF, Hansford R, Yang J, Caffo BS, Zviman MM, et al. Myocardial structural associations with local electrograms: a study of postinfarct ventricular tachycardia pathophysiology and magnetic resonance-based noninvasive mapping. Circ Arrhythm Electrophysiol. 2012;5:1081–90.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Sacher F, Roberts-Thomson K, Maury P, Tedrow U, Nault I, Steven D, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol. 2010;55:2366–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Stevenson WG, Wilber DJ, Natale A, Jackman WM, Marchlinski FE, Talbert T, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657–65.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40.PubMedCrossRefGoogle Scholar
  34. 34.
    Bigger Jr JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569–75.PubMedCrossRefGoogle Scholar
  35. 35.
    Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–90.PubMedCrossRefGoogle Scholar
  36. 36.
    Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.PubMedCrossRefGoogle Scholar
  37. 37.
    Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427–36.PubMedCrossRefGoogle Scholar
  40. 40.
    A comparison of anti-arrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Anti-arrhythmics vs Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576–83.CrossRefGoogle Scholar
  41. 41.
    Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study: a randomized trial of implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.PubMedCrossRefGoogle Scholar
  42. 42.
    Kuck K-H, Cappato R, Siebels J, Ruppel R, CASH Investigators. A comparison of anti-arrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. Circulation. 2000;102:748–54.PubMedCrossRefGoogle Scholar
  43. 43.
    Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur Heart J. 2000;21:2071–8.PubMedCrossRefGoogle Scholar
  44. 44.••
    Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275–83. This is the largest study to examine appropriate ICD programming, demonstrating that increasing the time to detection or rate of detection can improve mortality and reduce inappropriate therapies. It is possible that an even greater mortality benefit of ICD therapy can be seen than in previous ICD trials if they were programmed according to these settings.PubMedCrossRefGoogle Scholar
  45. 45.
    Epstein AE, DiMarco JP, Ellenbogen KA, Estes III NA, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408.PubMedCrossRefGoogle Scholar
  46. 46.
    O'Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013;99:534–41.PubMedCrossRefGoogle Scholar
  47. 47.
    McKeown PP, Muir AR. Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence. Heart. 2013;99:511–3.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Maron BJ. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circulation. 2010;74:2271–82.CrossRefGoogle Scholar
  49. 49.
    Gersh BJ, Maron BJ, Bonow RO, Ja D, Ma F, Link MS, et al. ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:e212–60.PubMedCrossRefGoogle Scholar
  50. 50.
    Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034–41.PubMedCrossRefGoogle Scholar
  51. 51.
    Rabinovich R, Muratore C, Iglesias R, Gonzalez M, Daru V, Valentino M, et al. Time to first shock in implantable cardioverter defibrillator (ICD) patients with Chagas cardiomyopathy. Pacing Clin Electrophysiol. 1999;22(1 Pt 2):202–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Sosa E, Scanavacca M, D'Avila A, Bellotti G, Pilleggi F. Radiofrequency catheter ablation of ventricular tachycardia guided by nonsurgical epicardial mapping in chronic Chagasic heart disease. Pacing Clin Electrophysiol. 1999;22(1 Pt 1):128–30.PubMedCrossRefGoogle Scholar
  53. 53.
    Leite LR, Fenelon G, Paes AT, de Paola AA. The impact of syncope during clinical presentation of sustained ventricular tachycardia on total and cardiac mortality in patients with chronic Chagasic heart disease. Arq Bras Cardiol. 2001;77:439–52.PubMedGoogle Scholar
  54. 54.
    Ca W, Williams RG, Bashore TM, Child JS, Connolly HM, Ja D, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;118:e714–833.CrossRefGoogle Scholar
  55. 55.
    Warnes CA. Transposition of the great arteries. Circulation. 2006;114:2699–709.PubMedCrossRefGoogle Scholar
  56. 56.
    Allen MR, Hayes DL, Warnes CA, Danielson GK. Permanent pacing in Ebstein's anomaly. Pacing Clin Electrophysiol. 1997;20:1243–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Murphy JG, Gersh BJ, McGoon MD, Mair DD, Porter C-BJ, Ilstrup DM, et al. Long-term outcome after surgical repair of isolated atrial septal defect. New Engl J Med. 1990;323:1645–50.PubMedCrossRefGoogle Scholar
  58. 58.
    Wilkinson JL, Smith A, Lincoln C, Anderson RH. Conducting tissues in congenitally corrected transposition with situs invs. Brit Heart J. 1978;40:41–8.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Opic P, van Kranenburg M, Yap SC, van Dijk AP, Budts W, Vliegen HW, et al. Complications of pacemaker therapy in adults with congenital heart disease: a multicenter study. Int J Cardiol. 2013;168:3212–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Odim J, Suckow B, Saedi B, Laks H, Shannon K. Equivalent performance of epicardial vs endocardial permanent pacing in children: a single institution and manufacturer experience. Ann Thoracic Surg. 2008;85:1412–6.CrossRefGoogle Scholar
  61. 61.
    McLeod C, Jost CA, Warnes C, Hodge II D, Hyberger L, Connolly H, et al. Epicardial vs endocardial permanent pacing in adults with congenital heart disease. J Interv Card Electrophysiol. 2010;28:235–43.PubMedCrossRefGoogle Scholar
  62. 62.
    Bouchardy J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Bottega N, et al. Atrial arrhythmias in adults with congenital heart disease. Circulation. 2009;120:1679–86.PubMedCrossRefGoogle Scholar
  63. 63.
    Gelatt M, Hamilton RM, McCrindle BW, Connelly M, Davis A, Harris L, et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll Cardiol. 1997;29:194–201.PubMedCrossRefGoogle Scholar
  64. 64.
    Cuypers JA, Opic P, Menting ME, Utens EM, Witsenburg M, Helbing WA, et al. The unnatural history of an atrial septal defect: longitudinal 35 year follow-up after surgical closure at young age. Heart. 2013;99:1346–52.PubMedCrossRefGoogle Scholar
  65. 65.
    Wi J, Choi J-Y, Shim J-M, Uhm J-S, Hwang H-J, Kim J-Y, et al. Fate of preoperative atrial fibrillation after correction of atrial septal defect. Circulation. 2013;77:109–15.CrossRefGoogle Scholar
  66. 66.•
    Koyak Z, Kroon B, de Groot JR, Wagenaar LJ, van Dijk AP, Mulder BA, et al. Efficacy of anti-arrhythmic drugs in adults with congenital heart disease and supraventricular tachycardias. Am J Cardiol. 2013;112:1461–7. This multicenter retrospective registry of over 7000 patients is the largest study of various anti-arrhythmic medications in those with CHD.PubMedCrossRefGoogle Scholar
  67. 67.
    Wells R, Khairy P, Harris L, Anderson CC, Balaji S. Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. Pacing Clin Electrophysiol. 2009;32:1313–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Fish FA, Gillette PC, Benson Jr DW. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Coll Cardiol. 1991;18:356–65.PubMedCrossRefGoogle Scholar
  69. 69.
    Snyder CS, Dobson G, Rollinson N, Graumann R. Suppression of intra-atrial reentrant tachycardia in patients with atrial overdrive pacing. Congenit Heart Dis. 2008;3:200–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Kannankeril PJ, Fish FA. Management of intra-atrial reentrant tachycardia. Curr Opin Cardiol. 2005;20:89–93.PubMedCrossRefGoogle Scholar
  71. 71.
    de Groot NMS, Atary JZ, Blom NA, Schalij MJ. Long-term outcome after ablative therapy of postoperative atrial tachyarrhythmia in patients with congenital heart disease and characteristics of atrial tachyarrhythmia recurrences. Circ Arrhythm Electrophysiol. 2010;3:148–54.PubMedCrossRefGoogle Scholar
  72. 72.
    Yap SC, Harris L, Downar E, Nanthakumar K, Silversides CK, Chauhan VS. Evolving electroanatomic substrate and intra-atrial reentrant tachycardia late after Fontan surgery. J Cardiovasc Electrophysiol. 2012;23:339–45.PubMedCrossRefGoogle Scholar
  73. 73.
    Yap SC, Harris L, Silversides CK, Downar E, Chauhan VS. Outcome of intra-atrial re-entrant tachycardia catheter ablation in adults with congenital heart disease: negative impact of age and complex atrial surgery. J Am Coll Cardiol. 2010;56:1589–96.PubMedCrossRefGoogle Scholar
  74. 74.
    Stamm C, Friehs I, Mayer JE, Zurakowski D, Triedman JK, Moran AM, et al. Long-term results of the lateral tunnel Fontan operation. J Thorac Cardiovasc Surg. 2001;121:28–41.PubMedCrossRefGoogle Scholar
  75. 75.
    Aboulhosn J, Williams R, Shivkumar K, Barkowski R, Plunkett M, Miner P, et al. Arrhythmia recurrence in adult patients with single ventricle physiology following surgical Fontan conversion. Congenit Heart Dis. 2010;5:430–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Balaji S, Daga A, Bradley DJ, Etheridge SP, Law IH, Batra AS, et al. An international multicenter study comparing arrhythmia prevalence between the intracardiac lateral tunnel and the extracardiac conduit type of Fontan operations. J Thorac Cardiovasc Surg. 2013. doi:10.1016/j.jtcvs2013.08.070.PubMedGoogle Scholar
  77. 77.
    Silka MJ, Bar-Cohen Y. A contemporary assessment of the risk for sudden cardiac death in patients with congenital heart disease. Pediatr Cardiol. 2012;33:452–60.PubMedCrossRefGoogle Scholar
  78. 78.
    Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998;32:245–51.PubMedCrossRefGoogle Scholar
  79. 79.
    Gallego P, Gonzalez AE, Sanchez-Recalde A, Peinado R, Polo L, Gomez-Rubin C, et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol. 2012;110:109–17.PubMedCrossRefGoogle Scholar
  80. 80.•
    Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;26:1944–54. This multicenter case-control study is the largest international analysis to examine SCD in those with CHD, demonstrating that even those with mild CHD defects may be at elevated risk of SCD.CrossRefGoogle Scholar
  81. 81.
    Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356:975–81.PubMedCrossRefGoogle Scholar
  82. 82.
    Khairy P, Dore A, Poirier N, Marcotte F, Ibrahim R, Mongeon F-P, et al. Risk stratification in surgically repaired tetralogy of Fallot. Exp Rev Cardiovasc Ther. 2009;7:755–62.CrossRefGoogle Scholar
  83. 83.
    Yap S-C, Roos-Hesselink JW, Hoendermis ES, Budts W, Vliegen HW, Mulder BJM, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur Heart J. 2007;28:1854–61.PubMedCrossRefGoogle Scholar
  84. 84.
    Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008;51:1685–91.PubMedCrossRefGoogle Scholar
  85. 85.
    Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009–17.PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.••
    Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944–53. This prospective study of the SICD demonstrated a low rate of complications and high rate of successful conversion of ventricular fibrillation during defibrillation threshold testing. The SICD has now become an option in a significant number of patients.PubMedCrossRefGoogle Scholar
  87. 87.
    Gold MR, Theuns DA, Knight BP, Sturdivant JL, Sanghera R, Ellenbogen KA, et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2012;23:359–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • H. Sawyer Gillespie
    • 1
  • Charles C. H. Lin
    • 1
  • Jordan M. Prutkin
    • 1
  1. 1.Division of CardiologyUniversity of WashingtonSeattleUSA

Personalised recommendations